July 2015 Our Ref: FOI.15.CAN0059 requesting information regarding Rebate and QIPP prescribing schemes in NHS Canterbury and Coastal Clinical Commissioning Group Could you please provide me with the details of any prescribing rebate schemes and QIPP prescribing schemes active within your CCG during the financial year 2014/15? Please answer the questions below: 1. Primary Care Prescribing Rebate Schemes Name of Scheme Drug(s) covered Nutricia enteral and sip feeds Pradaxa Rivaroxaban (Xarelto) GlucoRx diabetes monitoring products Insuman, Apidra, Lantus Degarelix Prostap DCS Companies involved in the scheme Nutricia Boehringer-Ingelheim Bayer GlucoRx Sanofi Ferring Takeda 2. What was the total income for the CCG from rebates during 2014/15? I can confirm the total income for NHS Canterbury and Coastal Clinical Commissioning Group from rebates during the financial period 2014-15 is 257,334. 3. QIPP Prescribing Schemes ECLIPSE LIVE alerts Name of Scheme Drug(s) covered Not relevant for quality measures
Uncomplicated UTI audit 8 consultations per prescriber standard 70% # Sore throat audit 8 consultations per prescriber standard 70% # Quinolone audit 6 consultations per prescriber standard 70% # PRIMIS audit tool Preferred tools cover COPD Drug(s) Covered by Project BNF 01.03.05 Cost effective use of Proton Pump Inhibitors (May BNF 01.03.05 Cost-effective use of Omeprazole (May BNF 01.05.01. Cost effective mesalazine (March BNF 01.06.04 Macrogol 3350-Cost effective options-cosmocol (first choice) or Laxido (March BNF 02.05 Angiotensin-II receptor antagonist optimisation BNF 02.05.04 Doxazosin Optimisation BNF 02.05.05 Perindopril arginine (Coversyl Arginine and Coversyl Arginine DROP list (DRugs of LOw Priority) BNF 02.06.01 Glyceryl Trinitrate sprays (June BNF 02.06.01 Isosorbide Mononitrate MR 60mg optimisation BNF 02.06.02 Amlodipine cost effective prescribing BNF 02.09 Clopidogrel / Dipyridamole Optimisation BNF 02.09 Clopidogrel optimisation (May BNF 02.12 Ezetimibe Optimisation BNF 02.12 Omega-3 fatty acid compounds BNF 02.12 Rosuvastatin BNF 02.12 Statin Optimisation BNF 03.01.01 Salbutamol inhalers- cost effective preparations BNF 03.01.02 LAMA Optimisation BNF 03.02 Cost effective budesonide/formoterol inhalers (High strength) (June BNF 03.02 Cost effective budesonide/formoterol inhalers (June
BNF 03.02 ICS/LABA Project 1 Options for pmdi preparations used at Step 3 of the BTS guidance (Updated June BNF 03.02 ICS/LABA Project 2 Options for DRY POWDER preparations used at Step 3 of the BTS guidance (Updated June BNF 03.02 ICS/LABA Project 3 Budesonide/formoterol- cost effective options for this preparation and safety considerations (Updated June BNF 03.02 ICS/LABA Project 4 Cost effective options for preparations containing fluticasone (Updated June BNF 03.02 Seretide 250/25 Evohaler monitoring BNF 03.03.02 Montelukast cost effective prescribing (May BNF 03.04.01 Antihistamines DROP topic (DRugs of LOw Priority) BNF 03.08 Decongestants, aromatic inhalations, cough mixtures. DROP list (DRugs of LOw Priority) BNF 04.02 Antipsychotics optimisation-olanzapine BNF 04.02 Antipsychotics optimisation-risperidone BNF 04.02.01 Amisulpride optimisation BNF 04.02.01 Aripiprazole dose optimisation BNF 04.02.01 Quetiapine immediate release vs Modified release (June BNF 04.02.01 use of branded generics for Quetiapine 150mg XL preparations. (June BNF 04.02.01 use of branded generics for Quetiapine 200mg XL preparations (June BNF 04.02.01 use of branded generics for Quetiapine 300mg XL preparations (June BNF 04.02.01 use of branded generics for Quetiapine 400mg XL preparations (June BNF 04.02.01 use of branded generics for Quetiapine 50mg XL preparations (June BNF 04.02.01 use of generic quetiapine 100mg BNF 04.02.01 use of generic quetiapine 150mg BNF 04.02.01 use of generic quetiapine 200mg BNF 04.02.01 use of generic quetiapine 25mg BNF 04.02.01 use of generic quetiapine 300mg BNF 04.03.03 Escitalopram cost effective prescribing (May BNF 04.03.03 Sertraline cost effective prescribing (May BNF 04.03.04 Venlafaxine optimisation
BNF 04.04 Modafinil cost effective prescribing BNF 04.05.01 Orlistat BNF 04.07 Co-codamol 30/500mg cost effective preparations BNF 04.07 Co-codamol 30/500mg cost effective preparations-soluble preparations BNF 04.07.01 Analgesia for minor/common ailments. DROP list (DRugs of LOw Priority) [Some overlap with Paracetamol project] BNF 04.07.01 Co-proxamol DROP list (DRugs of LOw Priority) BNF 04.07.02 Fentanyl lozenges DROP list (DRugs of LOw Priority) BNF 04.07.02 Fentanyl optimisation 12 micrograms BNF 04.07.02 Fentanyl optimisation 25 micrograms BNF 04.07.02 Fentanyl optimisation 50 micrograms BNF 04.07.02 Fentanyl optimisation 75 micrograms BNF 04.07.02 Oxycodone immediate release preparation-optimisation BNF 04.07.02 Oxycodone Modified Release Preparations-Optimisation 10mg BNF 04.07.02 Oxycodone Modified Release Preparations-Optimisation 20mg BNF 04.07.02 Oxycodone Modified Release Preparations-Optimisation 40mg BNF 04.07.02 Oxycodone Modified Release Preparations-Optimisation 5mg BNF 04.07.02 Oxycodone Modified Release Preparations-Optimisation 80mg BNF 04.07.02 Oxycodone/ Naloxone (Targinact ) DROP list (DRugs of LOw Priority) BNF 04.07.02 Tramacet DROP list (DRugs of LOw Priority) BNF 04.07.02 Tramadol Immediate release optimisation 50mg BNF 04.07.02 Tramadol Modified release optimisation 100mg BNF 04.07.02 Tramadol Modified release optimisation 150mg BNF 04.07.02 Tramadol Modified release optimisation 200mg BNF 04.07.02 Tramadol Modified release optimisation 50mg BNF 04.07.04.01 Triptans-Cost-effective use BNF 04.08.01 Pregabalin 25mg BNF 04.09.01 Pramipexole cost effective prescribing (May BNF 04.10.03 Buprenorphine sublingual cost effective prescribing (May BNF 04.11 Galantamine optimisation BNF 05.01.03 Minocycline. DROP list (DRugs of LOw Priority) BNF 06.01.01.02 Intermediate and long acting Insulins- Use NPH insulin first line BNF 06.01.01.03 Pen needles (Revised measure Oct 2014)
BNF 06.01.02 Gliclazide MR 30mg. DROP list (DRugs of LOw Priority) BNF 06.01.06 Blood Glucose Test strips BNF 06.01.06 Lancets BNF 06.03.02 Prednisolone 5mg Optimisation BNF 06.05.02 Desmopressin cost effective prescribing of nasal spray (May BNF 06.05.02 Desmopressin cost effective prescribing of tablets (May BNF 06.06.02 Bisphosphonate optimisation (May BNF 07.03.01 COC (Project 1) Gedarel 20/150 in place of Mercilon BNF 07.03.01 COC (Project 2) Millinette 20/75 in place of Femodette or Sunya 20/75 BNF 07.03.01 COC (Project 3) Gedarel 30/150 in place of Marvelon BNF 07.03.01 COC (Project 4) Lucette in place of Yasmin BNF 07.03.01 COC (Project 5) Millinette 30/75 in place of Femodene or Katya 30/75 BNF 07.03.01 COC (Project 6) Rigevidon in place of Microgynon 30, Ovranette or Levest BNF 07.03.01 COC (Project 7) TriRegol in place of Logynon BNF 07.03.01 POP Cerelle in place of Ceravette BNF 07.04.02 Tolterodine MR to Neditol XL BNF 07.04.05 Drugs for erectile dysfunction- generic sildenafil vs high cost alternatives (Amended Dec 2014) BNF 07.04.05 Sildenafil cost effective prescribing (May BNF 08.03.04 Anastrazole Optimisation (May BNF 08.03.04 Gonadorelin analogues (May (Preparations for one month duration of treatment) BNF 08.03.04 Gonadorelin analogues (May (Preparations for three months/12 weeks duration of treatment) BNF 09.04 Appendix 02.02 Nutritional supplements-ensure Cans BNF 09.04 Appendix 02.02.01.02 Nutritional supplements-aymes Shake is more cost effective than Complan Shake (March BNF 09.04.01 A02.05.01 Colief DROP list (DRugs of LOw Priority) BNF 09.04.01 A02.05.01 VSL#3 DROP list (DRugs of LOw Priority) BNF 09.06 Vitamins and minerals-unlicensed BNF 09.06.04 Calcium and Vitamin D -DROP list (DRugs of LOw Priority) BNF 10.01.01 Ibuprofen and naproxen as % of all NSAIDs BNF 10.01.05 Glucosamine
BNF 10.03.02 Ibruprofen gel 10% switch to branded generic BNF 10.03.02 Ibuprofen gel 5% to branded generic BNF 10.03.02 Movelat to Algesal BNF 11.06 Dorzolamide (and combination products) optimisation BNF 11.06 Latanoprost (and combination products) optimisation BNF 12.02.01 Mometasone nasal spray cost effective prescribing (May BNF 12.03.03 Nystatin suspension optimisation BNF 13.02.01 Cost effective emollients - ZeroAQS (Aqueous Cream Alternative) BNF 13.02.01 Cost effective emollients - Zerobase (Diprobase Cream Alternative) BNF 13.02.01 Cost effective emollients - Zerocream (E45 Cream Alternative) BNF 13.02.01 Cost effective emollients - Zeroderm (Epaderm alternative) BNF 13.02.01 Cost effective emollients - Zerodouble Gel (Doublebase Gel Alternative) BNF 13.02.01 Cost effective emollients - Zeroguent Cream (Unguentum M Cream Alternative) BNF 13.02.01.01 Emollient bath and shower - cost effective preparations BNF 13.10 Fflornithine (Vaniqa) DROP list-drug of Low Priority BNF 13.10.02 Topical Antifungals DROP list (DRugs of LOw Priority) BNF 13.6.1 Cost effective Lymecycline Preparation BNF 14.04 Vaccinations for Hepatitis B and Meningitis ACWY (June BNF 14.04 Travel vaccines (June